News ArticleSudeep Pharma Limited Posts ₹5,181.11 Lakhs Net Profit for Q2 Ending September 30, 2026
Company records ₹19,669.91 lakhs revenue from operations and ₹7,103.25 lakhs profit before tax in the quarter; board approves unaudited consolidated results
Sudeep Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a net profit of ₹5,181.11 lakhs for the quarter. Total revenue from operations reached ₹19,669.91 lakhs with total income of ₹20,268.34 lakhs. The Board approved these results, with a consolidated profit before tax of ₹7,103.25 lakhs for the quarter.
Sudeep Pharma Limited
Financial Results
Sudeep Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a net profit after tax of ₹5,181.11 lakhs for the quarter.
The company reported revenue from operations of ₹19,669.91 lakhs for the quarter ended September 30, 2026, and total income including other income stood at ₹20,268.34 lakhs.
Total expenses were ₹13,165.09 lakhs for the quarter, leading to a profit before tax of ₹7,103.25 lakhs.
Tax expenses for the period were ₹1,922.14 lakhs, including current tax of ₹1,821.77 lakhs and deferred tax of ₹100.37 lakhs.
For the half year ending September 30, 2026, Sudeep Pharma recorded a profit after tax of ₹9,239.80 lakhs on total income of ₹36,639.93 lakhs.
The results include those of the Parent company and its subsidiaries, with one subsidiary’s financials not reviewed but deemed not material to the group’s consolidated results.
Highlights
- Net profit after tax for quarter ended September 30, 2026: ₹5,181.11 lakhs
- Revenue from operations for the quarter: ₹19,669.91 lakhs
- Profit before tax for the quarter: ₹7,103.25 lakhs
- Total expenses for the quarter: ₹13,165.09 lakhs
- Unaudited consolidated results approved by the Board on October 28, 2026
Key Data Snapshot
Financial performance
- Sudeep Pharma posted a net profit of ₹5,181.11 lakhs for the quarter ended September 30, 2026, compared to ₹4,677.82 lakhs for the same quarter in the prior year.
- Revenue from operations increased to ₹19,669.91 lakhs from ₹16,266.62 lakhs year-over-year.
- Expenses increased to ₹13,165.09 lakhs from ₹11,329.80 lakhs year-over-year.
- The Board approved unaudited standalone and consolidated results for Q2 and half year ending September 30, 2026.
Regulatory and governance context
- The results were prepared in compliance with Indian Accounting Standard 34 (Ind AS 34) and SEBI Listing Regulations.
- The limited review was conducted by B S R and Co Chartered Accountants, who did not modify their conclusion on the financial statement.
- One subsidiary's financial results were not reviewed but considered immaterial to the consolidated results.
Background and context
- The consolidated results include Sudeep Pharma Limited and its wholly owned subsidiaries Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V, Sudeep Advanced Materials Private Limited, and the step down subsidiary Nutrition Supplies & Services (Ireland) Limited.
- The Board meeting approving the results was held on October 28, 2026.
Highlights
- Net profit after tax for quarter ended September 30, 2026: ₹5,181.11 lakhs
- Revenue from operations for the quarter: ₹19,669.91 lakhs
- Profit before tax for the quarter: ₹7,103.25 lakhs
- Total expenses for the quarter: ₹13,165.09 lakhs
- Unaudited consolidated results approved by the Board on October 28, 2026
Disclosures
- Regulation 30(6) and Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Welspun Corp Reports Q2 FY2027 Financials and Approves $115M US Capacity Expansion and $125M Jordan JV
Welspun Corp Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, approved a $115 million capital expenditure to expand its US HSAW spiral pipe facility by 225 KMTPA, and sanctioned a $125 million joint venture with Perma-Pipe to establish spiral pipe manufacturing and coating facilities in Jordan.
Read Full Story
Ambuja Cements Acquires 26% Equity Stake in SWE Renewables and Reports Q2 FY2027 Financials
Ambuja Cements Limited has acquired a 26% stake in renewable energy firm SWE Renewables Limited and announced its unaudited financial results for the quarter and half year ended September 30, 2026, showing a profit after tax of ₹618 crore for the half year.
Read Full Story
Asian Paints Declares Rs. 5.75 Interim Dividend Alongside Q2 and H1 FY 2027 Financial Results
Asian Paints Limited announced its audited standalone and unaudited consolidated financial results for the quarter and half year ended 30th September 2026. The company also declared an interim dividend of Rs. 5.75 per equity share for the financial year ending 31st March 2027.
Read Full Story
